NZ596616A - Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase - Google Patents

Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase

Info

Publication number
NZ596616A
NZ596616A NZ596616A NZ59661610A NZ596616A NZ 596616 A NZ596616 A NZ 596616A NZ 596616 A NZ596616 A NZ 596616A NZ 59661610 A NZ59661610 A NZ 59661610A NZ 596616 A NZ596616 A NZ 596616A
Authority
NZ
New Zealand
Prior art keywords
triazolothiadiazole
aminopyrazole
inhibitors
met
agent
Prior art date
Application number
NZ596616A
Other languages
English (en)
Inventor
David Lauffer
Pan Li
Kira Mcginty
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42346870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ596616(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NZ596616A publication Critical patent/NZ596616A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ596616A 2009-05-28 2010-05-27 Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase NZ596616A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18178609P 2009-05-28 2009-05-28
PCT/US2010/036312 WO2010138665A1 (en) 2009-05-28 2010-05-27 Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase

Publications (1)

Publication Number Publication Date
NZ596616A true NZ596616A (en) 2013-05-31

Family

ID=42346870

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596616A NZ596616A (en) 2009-05-28 2010-05-27 Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase

Country Status (25)

Country Link
EP (1) EP2435443B1 (enExample)
JP (1) JP5686796B2 (enExample)
KR (1) KR20120030110A (enExample)
CN (1) CN102459283B (enExample)
AR (1) AR076617A1 (enExample)
AU (1) AU2010254055B2 (enExample)
BR (1) BRPI1012037A2 (enExample)
CA (1) CA2762190A1 (enExample)
CL (1) CL2011002946A1 (enExample)
DK (1) DK2435443T3 (enExample)
ES (1) ES2433090T3 (enExample)
HR (1) HRP20130986T1 (enExample)
IL (1) IL216581A (enExample)
MX (1) MX2011012521A (enExample)
NZ (1) NZ596616A (enExample)
PL (1) PL2435443T3 (enExample)
PT (1) PT2435443E (enExample)
RS (1) RS53011B (enExample)
RU (1) RU2552993C2 (enExample)
SG (1) SG176574A1 (enExample)
SI (1) SI2435443T1 (enExample)
TW (1) TWI491614B (enExample)
UA (1) UA106082C2 (enExample)
WO (1) WO2010138665A1 (enExample)
ZA (1) ZA201108655B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2762186A1 (en) * 2009-05-28 2010-12-02 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-met protein kinase
EP2576568A1 (en) 2010-05-27 2013-04-10 Vertex Pharmaceuticals Incorporated An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase
TR201113223A2 (tr) * 2011-12-29 2012-06-21 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ A. Ş. Pemetrekset disodyum hazırlanmasına yönelik tek basamaklı işlem.
KR101373912B1 (ko) 2012-03-26 2014-03-13 중앙대학교 산학협력단 Shp-2의 활성을 특이적으로 저해하는 조성물 및 이의 제조방법
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN109897054B (zh) * 2017-12-08 2021-12-10 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
ZA200501536B (en) * 2002-08-14 2006-10-25 Vertex Pharma Protein kinase inhibitors and uses thereof
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 c-Met의 억제제 및 이의 용도
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
CN101678014B (zh) * 2007-05-21 2012-12-12 Sgx药品公司 杂环激酶调节剂
JP5596047B2 (ja) * 2008-11-19 2014-09-24 バーテックス ファーマシューティカルズ インコーポレイテッド c−Metタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
CA2762186A1 (en) * 2009-05-28 2010-12-02 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-met protein kinase

Also Published As

Publication number Publication date
AU2010254055A1 (en) 2011-12-15
DK2435443T3 (da) 2013-10-28
EP2435443B1 (en) 2013-07-31
HRP20130986T1 (hr) 2013-11-22
SI2435443T1 (sl) 2013-12-31
JP5686796B2 (ja) 2015-03-18
AU2010254055B2 (en) 2016-01-14
CN102459283A (zh) 2012-05-16
ES2433090T3 (es) 2013-12-09
PL2435443T3 (pl) 2014-01-31
PT2435443E (pt) 2013-10-31
HK1169105A1 (en) 2013-01-18
RU2011153613A (ru) 2013-07-10
UA106082C2 (uk) 2014-07-25
CL2011002946A1 (es) 2012-07-27
CA2762190A1 (en) 2010-12-02
IL216581A (en) 2014-02-27
RS53011B (sr) 2014-04-30
BRPI1012037A2 (pt) 2016-05-17
SG176574A1 (en) 2012-01-30
EP2435443A1 (en) 2012-04-04
CN102459283B (zh) 2014-11-12
TW201100436A (en) 2011-01-01
ZA201108655B (en) 2013-01-30
TWI491614B (zh) 2015-07-11
JP2012528186A (ja) 2012-11-12
RU2552993C2 (ru) 2015-06-10
IL216581A0 (en) 2012-02-29
WO2010138665A1 (en) 2010-12-02
KR20120030110A (ko) 2012-03-27
MX2011012521A (es) 2012-01-30
AR076617A1 (es) 2011-06-22

Similar Documents

Publication Publication Date Title
NZ596616A (en) Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
WO2014151871A3 (en) Jak2 and alk2 inhibitors and methods for their use
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
MX2007005546A (es) Tiazoles de 5-heteroarilo y su uso como inhibidores p13k.
WO2008104175A3 (en) Novel phosphodiesterase inhibitors
MY150661A (en) Pyridin-3-yl derivatives as immunomodulating agents
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
MX2009011802A (es) Imidazoquinolinas con propiedades inmunomoduladoras.
WO2009155121A3 (en) Inhibitors of pi3 kinase
GEP20156389B (en) Oxazolidin-2-one compounds and their usage as pi3ks inhibitors
CL2009001152A1 (es) Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
WO2008067257A8 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007084560A8 (en) INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
PH12012500355A1 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
IL193500A (en) Pharmaceuticals including n-oxide of Winka alkaloid analogue for the treatment of hyper-proliferative diseases
WO2008143649A3 (en) Novel oxazolidinone compounds as antiinfective agents
WO2010047737A3 (en) Antimicrobial indoline compounds for treatment of bacterial infections
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
NZ592168A (en) Nitrogenous heterocyclic compounds, preparation thereof, and use thereof as antibacterial agents

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 MAY 2017 BY COMPUTER PACKAGES INC

Effective date: 20140528

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3155030, VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MASSACHUSETTS 02210, US

Effective date: 20150127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2018 BY COMPUTER PACKAGES INC

Effective date: 20170502

LAPS Patent lapsed